Lexaria Bioscience Corp. — Director's Dealing 2023

Oct 30, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lexaria Bioscience Corp. (LEXX)
CIK: 0001348362
Period of Report: 2023-10-26

Reporting Person: DOCHERTY JOHN MARTIN (Director, President)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-10-26	Stock Options	$1.15	A	30000	Acquired	2028-10-26	Common Shares (30000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
common shares	54075	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Options	$3	2025-04-23	Common Shares (13334)	13334	Direct
Stock Options	$3	2026-04-26	Common Shares (18000)	31334	Direct
Stock Options	$3	2026-06-08	Common Shares (18334)	49668	Direct
Stock Options	$3	2026-09-01	Common Shares (15000)	64668	Direct
Stock Options	$2.91	2027-08-29	Common Shares (30000)	94668	Direct

Footnotes

F1: Repriced from $9.60 pursuant to shareholder approval received on May 9, 2023

F2: Repriced from $5.31 pursuant to shareholder approval received on May 9, 2023

F3: Repriced from $7.08 pursuant to shareholder approval received on May 9, 2023

F4: Repriced from $6.23 pursuant to shareholder approval received on May 9, 2023